The
diuretic bumetanide, which acts by blocking the
Na-K-Cl cotransporter (NKCC), is widely used to inhibit neuronal NKCC1, particularly when NKCC1 expression is abnormally increased in
brain diseases such as
epilepsy. However,
bumetanide poorly penetrates into the brain and, in rodents, is rapidly eliminated because of extensive oxidation of its N-butyl sidechain, reducing the translational value of rodent experiments. Inhibition of oxidation by
piperonyl butoxide (PBO) has previously been reported to increase the half-life and
diuretic activity of
bumetanide in rats. Here we studied whether inhibition of
bumetanide metabolism by PBO also increases brain levels of
bumetanide in rats, and whether this alters pharmacodynamic effects in the kindling model of
epilepsy. Furthermore, we studied the effects of PBO in mice. Mice eliminated
bumetanide less rapidly than rats (elimination half-life 47 min vs. 13 min). Pretreatment with PBO increased the half-life in mice to average values (70 min) previously determined in humans, and markedly elevated brain levels of
bumetanide. In rats, the increase in plasma and brain levels of
bumetanide by PBO was less marked than in mice. PBO significantly increased the
diuretic activity of
bumetanide in rats and, less effectively, in mice. In epileptic mice,
bumetanide (with PBO) did not suppress spontaneous
seizures. In the rat kindling model,
bumetanide (with or without PBO) did not exert
anticonvulsant effects on fully kindled
seizures, but dose-dependently altered kindling development. These data indicate that PBO offers a simple means to enhance the translational properties of rodent experiments with
bumetanide, particularly when using mice.